About PHD finger protein 23
PHD finger protein 23 (PHF23) is a protein
from Homo sapiens identified by UniProt accession
Q9BUL5, 403 residues long.
MolForge cross-references it against 0 known binders and
39 disease associations.
Target properties
| Protein name | PHD finger protein 23 |
|---|
| UniProt accession | Q9BUL5 |
|---|
| Gene | PHF23 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 403 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (39)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.24
- lymphocyte percentage of leukocytes · score 0.22
- neutrophil percentage of leukocytes · score 0.20
- vital capacity · score 0.12
- platelet count · score 0.12
- birth weight · score 0.11
- non-small cell lung carcinoma · score 0.08
- alkaline phosphatase measurement · score 0.08
- systolic blood pressure · score 0.07
- metabolite measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BUL5-F1 | alphafold | PREDICTED | 60.30 | — |
Amino-acid sequence (403 residues)
MLEAMAEPSP EDPPPTLKPE TQPPEKRRRT IEDFNKFCSF VLAYAGYIPP SKEESDWPAS GSSSPLRGES AADSDGWDSA PSDLRTIQTF VKKAKSSKRR AAQAGPTQPG PPRSTFSRLQ APDSATLLEK MKLKDSLFDL DGPKVASPLS PTSLTHTSRP PAALTPVPLS QGDLSHPPRK KDRKNRKLGP GAGAGFGVLR RPRPTPGDGE KRSRIKKSKK RKLKKAERGD RLPPPGPPQA PPSDTDSEEE EEEEEEEEEE EMATVVGGEA PVPVLPTPPE APRPPATVHP EGVPPADSES KEVGSTETSQ DGDASSSEGE MRVMDEDIMV ESGDDSWDLI TCYCRKPFAG RPMIECSLCG TWIHLSCAKI KKTNVPDFFY CQKCKELRPE ARRLGGPPKS GEP
Explore PHD finger protein 23 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets